One of the most exciting recent developments supported by the Michael J. Fox Foundation is the announcement of human trials of MCC950, a once daily pill therapy targeting the brain inflammation present in all PD patients that may stop Parkinson’s disease “in its tracks.” The progress of MCC950 is moving quickly with Phase 2 human testing as early as 2020. This is a world first advancement, because it stops the death of brain cells in Parkinson’s sufferers rather than managing symptoms. The development of MCC950 marks another significant milestone in the Michael J. Fox Foundation’s short story, and is a result of our collective efforts in the fight against Parkinson’s, something Kickin’ Parkinson’s is proud to be part of!